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Objective: To evaluate the effects of postoperative anticancer chemo-
therapy for small cell lung cancer on LCNEC.
Methods: Twenty-four patients who had undergone resection of 
LCNEC in our hospital between 1986 and 2004 were classiﬁed, accord-
ing to the presence or absence of postoperative adjuvant chemotherapy 
and to its regimen, into group A which received two or more courses 
of a platinum-based regimen with VP-16 or CPT-11 for small cell lung 
cancer, group B which received other regimens, and group C which re-
ceived no postoperative adjuvant chemotherapy, and evaluated in terms 
of 5-year recurrence-free survival and 5-year survival rates.
Results: The subjects consisted of 24 men and 2 women, with a mean 
age of 68 years, and all were smokers. Six patients had stage I cancer, 4 
stage II cancer, 13 stage III cancer, and 1 stage IV cancer. Six patients 
(25%) belonged to group A, 4 (1 received MVP 2 courses, 1 CAV 1 
courses, and 2 UFT courses) to group B, and 14 to group C. The 5-year 
recurrence-free survival and 5-year survival rates in group A were 50% 
each, whereas all patients in group B died within 2 years, and the 5-
year recurrence-free survival and 5-year survival rates in group C were 
25% and 34%, respectively.
Discussion: No signiﬁcant intergroup differences were observed, be-
cause of the small number of patients studied. However, the prognosis 
in group A was slightly better than that in groups B and C. Since the 
present study evaluated a small number of patients in all stages of can-
cer, the current issue remained unresolved. Therefore, further studies 
are needed in more patients.
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Background: We have reported an efﬁcacy of the combination of 
cisplatin on day 1 and docetaxel on days 1, 8 and 15 every 4 weeks for 
the treatment of previously untreated patients with non-small cell lung 
cancer (NSCLC). Concurrent radiation applied to cisplatin-based che-
motherapy with new anticancer agents is expected for locally advanced 
NSCLC. We evaluated the efﬁcacy and safety of cisplatin and weekly 
docetaxel combined with thoracic radiotherapy for patients with Stage 
III advanced NSCLC. 
Methods: We identiﬁed 34 eligible patients with locally advanced 
NSCLC and good performance status (PS) (ECOG; 0 or 1) who had 
not received prior treatment and who were under 75 years old. Their 
median age was 63 years (range, 45-74 years), 32 patients were male 
(94.1%), two (5.9%) were female, 30 (88.2%) had PS 0, 4 (11.8%) had 
PS 1, 3 had Stage IIIA (8.9%), and 31 had Stage IIIB (91.1%). Tumor 
histology included adenocarcinoma (55.9 %) and epidermoid (41.2 %). 
The patients received intravenous infusions of docetaxel (20 mg/m2, 
days 1, 8, 15) and cisplatin (80mg/m2, day 1) with standard thoracic 
concurrent radiation (60Gy, 2Gy/day).
Result: Grade 3/4 neutropenia was recorded in four patients (12 %), 
but there were no episodes of neutropenic fever. Nonhematologic toxic-
ities were also mild, consisting mainly in grade II anorexia. Esophagitis 
and pulmonary toxicities over Grade 3 were observed in 18 % and 12 
%, respectively. One complete response and 19 partial responses were 
observed and the objective response rate was 59.6 %. The median sur-
vival time was 26.4 months, and the 1-year survival rate was 76.0 %. 
Conclusion: Cisplatin with weekly administration of docetaxel com-
bined with concurrent radiotherapy is a feasible and effective regimen 
against advanced NSCLC.
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Background: In locally advanced non-small cell lung cancer(NSCLC), 
concurrent chemoradiotherapy(CCRT) becomes the leading therapeutic 
modality. But there are still many controversies in the chemotherapeu-
tic regimens and in the radiation methods. 
Materials and Methods: 27 NSCLC patients of clinical stage IIIB, 2 
patients with stage IIIA were enrolled since December 2002. The per-
formance status of ECOG grade 0 or 1 was in 22 patients(75.9%) and 
the others were grade 2. Squamous cell cancer was the most common 
(62%), followed by adenocarcinoma (31%). Cisplatin(30mg/m2) and 
gemcitabine(500mg/m2) were administered every two weeks while 50.4 
Gy(28 fractions) was irradiated on the tumor site. Booster irradiation of 
18 Gy (10 fractions) was administered unless the disease progressed. 
Two or three cycles of consolidation chemotherapy were done with 
gemcitabine(1200mg/m2 1st and 8thday) and cisplatin(60mg/m2) every 
three weeks. 
Results: During CCRT, severe esophagitis(>grade III) was serious 
complication(51.6%), followed by granulocytopenia(72.2%) and 
pneumonitis(20.7%). But they were mostly grade 2 and well managed 
by medical treatments and no patients withheld the treatment. After the 
consolidation chemotherapy, 3 patients(10.3%) had complete remis-
sion, 21 patients (72.4%) showed partial remission, and in 4 patients, 
the disease was stable, and in 1 patients it progressed. 
Median survival time was 16 months( 95% CI;2.4-39.2 months), The 
survival rates in one, two, and three years are 62.7%, 43.9%, 20%, 
respectively. 
Conclusion: The response rate and survival time of biweekly gem-
citabine plus cisplatin chemotherapy with concurrent radiotherapy 
was encouraging in patients with locally advanced NSCLC. However, 
treatment related toxicities were signiﬁcant, thus further modiﬁcation 
of therapy seems to be warranted. 
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